ATE388151T1 - Trizyklische purin derivate und deren analoga als inhibitoren des cytokinsignals - Google Patents

Trizyklische purin derivate und deren analoga als inhibitoren des cytokinsignals

Info

Publication number
ATE388151T1
ATE388151T1 AT05021060T AT05021060T ATE388151T1 AT E388151 T1 ATE388151 T1 AT E388151T1 AT 05021060 T AT05021060 T AT 05021060T AT 05021060 T AT05021060 T AT 05021060T AT E388151 T1 ATE388151 T1 AT E388151T1
Authority
AT
Austria
Prior art keywords
tricyclic
analogs
inhibitors
purine derivatives
cytokine signaling
Prior art date
Application number
AT05021060T
Other languages
English (en)
Inventor
Baoqing Gong
Michael Coon
J Peter Klein
Original Assignee
Cell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Inc filed Critical Cell Therapeutics Inc
Application granted granted Critical
Publication of ATE388151T1 publication Critical patent/ATE388151T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT05021060T 2000-11-29 2001-11-09 Trizyklische purin derivate und deren analoga als inhibitoren des cytokinsignals ATE388151T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/725,016 US6586429B2 (en) 2000-11-29 2000-11-29 Tricyclic fused xanthine compounds and their uses

Publications (1)

Publication Number Publication Date
ATE388151T1 true ATE388151T1 (de) 2008-03-15

Family

ID=24912791

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05021060T ATE388151T1 (de) 2000-11-29 2001-11-09 Trizyklische purin derivate und deren analoga als inhibitoren des cytokinsignals

Country Status (11)

Country Link
US (2) US6586429B2 (de)
EP (2) EP1347976A2 (de)
JP (1) JP4275947B2 (de)
CN (1) CN1533391A (de)
AT (1) ATE388151T1 (de)
AU (1) AU2001297649A1 (de)
CA (1) CA2426538A1 (de)
DE (1) DE60133149T2 (de)
ES (1) ES2302108T3 (de)
MX (1) MXPA03004450A (de)
WO (1) WO2002068421A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006074051A2 (en) * 2004-12-30 2006-07-13 Diakine Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION
US7435740B2 (en) * 2005-02-02 2008-10-14 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
AU2006278215A1 (en) * 2005-08-10 2007-02-15 Smithkline Beecham Corporation Xanthine derivatives as selective HM74A agonists
JP5259408B2 (ja) 2005-08-29 2013-08-07 ユニバーシティ オブ バージニア パテント ファンデーション リソフィリン類縁体とその使用方法
US8871764B2 (en) 2005-08-29 2014-10-28 University Of Virginia Patent Foundation Lisofylline analogs and methods for use
KR101086456B1 (ko) * 2009-10-15 2011-11-25 한국원자력의학원 이미다조퓨린 유도체를 포함하는 ＴＧＦ-β 활성 저해용 조성물
CN109721605B (zh) * 2017-10-31 2022-03-11 维眸生物科技（上海）有限公司 一种免疫细胞迁徙抑制剂
CN107840851A (zh) * 2017-12-21 2018-03-27 扬州大学 吲哚螺吡咯嗪化合物及其合成方法
CN115197228A (zh) * 2022-07-13 2022-10-18 河南师范大学 吡唑啉酮[螺]二氢酞嗪和1,3-茚二酮[螺]二氢酞嗪类化合物的合成方法
CN116509870B (zh) * 2023-03-29 2025-12-23 大连理工大学 油菜花粉碱a在神经保护和脑疾病防治方面的新用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3770741A (en) * 1968-01-05 1973-11-06 Pfizer 1,3-dimethyl - 1,2,3,4 - tetrahydroheterocyclo(x,y-f)purine-2,4-diones and method for their preparation
US4515795A (en) 1968-11-25 1985-05-07 Hoechst Aktiengesellschaft Pharmaceutical compositions
FR2157726A1 (en) * 1971-10-29 1973-06-08 Brun Lab Sa Le Cyclic derivs of 8-aminotheophylline - with analgesic activity
FR2303551A1 (fr) * 1975-03-12 1976-10-08 Brun Lab Sa Le Derives de la 8-amino theophylline, leur procede de preparation et leurs applications
GB2006765B (en) * 1978-10-06 1982-12-08 Chinoin Gyogyszer Es Vegyeszet Purine derivatives their preparation and pharmaceutical compositions containing them
US4228164A (en) * 1978-11-07 1980-10-14 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Condensed purine derivatives useful for improving peripheral circulation
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
US5039666A (en) 1990-10-30 1991-08-13 Hoechst-Roussel Pharmaceuticals Inc. Aminoglycoside composition having substantially reduced nephrotoxicity induced by the aminoglycoside
US5648357A (en) 1992-03-04 1997-07-15 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
US5804584A (en) * 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
WO1994024133A1 (en) 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
AU1868195A (en) 1994-01-28 1995-08-15 Cell Therapeutics, Inc. Cell signaling inhibitors
CA2183562A1 (en) 1994-02-18 1995-08-24 J. Peter Klein Intracellular signalling mediators
US5801182A (en) 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
ATE226200T1 (de) 1994-05-16 2002-11-15 Cell Therapeutics Inc Asymmetrische synthese von chiralen sekondären alkoholen
US5643893A (en) 1994-06-22 1997-07-01 Macronex, Inc. N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
US6075029A (en) 1998-01-02 2000-06-13 Cell Therapeutics, Inc. Xanthine modulators of metabolism of cellular P-450
JP2002541258A (ja) 1999-04-09 2002-12-03 セル セラピューティクス インコーポレーテッド インターリューキン−１２シグナルを阻害するための治療用化合物及びその使用方法

Also Published As

Publication number Publication date
CA2426538A1 (en) 2002-09-06
CN1533391A (zh) 2004-09-29
DE60133149D1 (de) 2008-04-17
MXPA03004450A (es) 2004-05-04
EP1347976A2 (de) 2003-10-01
JP2004519480A (ja) 2004-07-02
JP4275947B2 (ja) 2009-06-10
EP1690864A2 (de) 2006-08-16
WO2002068421A2 (en) 2002-09-06
DE60133149T2 (de) 2009-07-02
US7247630B2 (en) 2007-07-24
AU2001297649A1 (en) 2002-09-12
US6586429B2 (en) 2003-07-01
ES2302108T3 (es) 2008-07-01
US20020103211A1 (en) 2002-08-01
EP1690864A3 (de) 2006-12-27
US20030162801A1 (en) 2003-08-28
WO2002068421A3 (en) 2003-07-31
EP1690864B1 (de) 2008-03-05

Similar Documents

Publication Publication Date Title
DE60118003D1 (de) Harnstoffderivate und ihre verwendung
EE200300324A (et) Asendatud alküülamiini derivaadid ja nende kasutamismeetodid
BRPI0411825B8 (pt) inibidores de p38 quinase a base de heterociclo de 5 elementos, seus processos de preparação e seus usos, bem como composição farmacêutica
ATE453636T1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
WO2004106492A3 (en) Bicyclicpyrimidones and their use to treat diseases
ATE457313T1 (de) Bicyclische heterocyclische p-38-kinase- inhibitoren
IL151695A0 (en) Substituted beta-carbolines with ikb-kinase inhibiting activity
ATE404552T1 (de) Substituierte isochinolinderivate und anwendungsverfahren
ATE424402T1 (de) Imidazopyridinverbindungen
EA200400735A1 (ru) 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ
EA200701296A1 (ru) 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства
DE602004022668D1 (de) 5-gliedrige heterocyclische p-38 inhibitoren
MY177111A (en) Substituted amide derivatives and methods of use
PE20060775A1 (es) Derivados de pirrolidilo de compuestos heteroaromaticos como inhibidores de fosfodiesterasa
DE60323133D1 (de) Cyclohexylverbindungen als ccr5-antagonisten
ATE388151T1 (de) Trizyklische purin derivate und deren analoga als inhibitoren des cytokinsignals
UY27658A1 (es) Derivados de nicotinamida y una sal de tiotropio en combinación para el tratamiento de enfermedades
MXPA03008635A (es) Compuestos de dihidropirimidina ciano sustituidos y su uso para tratar enfermedades.
YU75803A (sh) Nova dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
UY29239A1 (es) Nuevos derivados de piridotienopirimidina
ES2173435T3 (es) Derivados condensados de 2,3-benzodiazepinas y su utilizacion como agentes inhibidores de receptores de ampa.
EA200701758A1 (ru) Замещённые арильные производные 1,4-пиразина
PT1259229E (pt) Utilizacao de benzotieno-[2,3-d]-pirimidinas com uma accao inibidora da pde v no tratamento do disfuncao erectil
DE602004010186D1 (de) Diazaspiropiperidinderivate als inhibitoren von glycintransporter 1 und glycintransporter 2
EA200501053A1 (ru) Производные 1,2,4-триаминобензола, пригодные для лечения расстройств центральной нервной системы

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties